You searched for drug development - Page 3 of 213

BenevolentAI Artificial Intelligence Fundraising

News and Trends 19 Apr 2018

Major $115M Fundraising Fuels AI Drug Development

BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […]

April 19, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 26 Feb 2018

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […]

February 26, 2018 - 2 minutesmins - By Alexander Burik

Interview 14 Feb 2018

This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why

Our second interview at Refresh in Vienna was with Peter Llewellyn-Davies, the founder of Accellerate Partners and Apeiron’s CFO and CBO. He told us how he found himself at the biotech and shared the lessons he learned on his way there. Peter Llewellyn-Davies founded Accellerate Partners in 2012, which offers services including corporate expansion, funding […]

February 14, 2018 - 5 minutesmins - By Alex Dale

owkin artificial intelligence drug development

More News! 17 Jan 2018

€9M Round for AI Algorithms to Speed up Drug Development

Owkin has raised $11M(€9M) in a Series A round to fund its artificial intelligence platform for medical research and drug discovery. Owkin, based in New York and Paris, was founded in 2016 to develop machine learning algorithms that can deal with the overabundance of information in biology to optimize the drug development process. The company […]

January 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Step Pharma will use the proceeds of its first fundraising round to support the development of immunomodulators for autoimmune diseases towards the clinic. Step Pharma develops inhibitors targeting an enzyme called cytidine nucleotide triphosphate (CTPS1) for the treatment of a range of autoimmune diseases. The company is working on several candidates, the most advanced of which […]

November 21, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […]

November 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 26 Oct 2017

The FDA Recruits British Organs-on-Chips to Speed Up Drug Development

CN Bio Innovations and the FDA have entered a research collaboration to better predict drug safety in drug development by using human organs-on-chips. CN Bio Innovations, a spin-out from the University of Oxford, will be working with scientists from the FDA’s Centre for Drug Evaluation and Research with the aim of integrating organ-on-a-chip technology in the […]

October 26, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

NanoTemper: the Game-changer for Drug Development Technologies

“Getting better drugs faster” is what biochemist Dr. Stefan Duhr and biophysicist Dr. Philipp Baaske envisioned when they started building NanoTemper Technologies. Established in 2008 in Munich, NanoTemper Technologies provides innovative solutions to help develop biological products. For the past 8 years, many great products have been launched like the Monolith instruments series – providing MicroScale Thermophoresis (MST), an easy, fast […]

September 5, 2016 - 4 minutesmins - By Jerome Topsent

ergomed clinical trial smo operation andrew mackie drug development pipeline oncology autoimmune rare disease smo

News and Trends 10 May 2016

This UK Company told us how they Optimise Drug Development and turn a Profit

Drug development is complex, requiring a high level of many different skills as well as an insane amount of cash to put it on the market. Having an innovative business model can be one solution to make it affordable. That is what Ergomed, a profitable UK company is doing: combining Clinical Research Organisation (CRO) services and […]

May 10, 2016 - 4 minutesmins - By Dani Bancroft

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 21 Nov 2022

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us